ReviewEuropean journal of pharmacology2011
Cardiovascular effects of melanocortins.
Review in European journal of pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Cardiometabolic regulation by adipocyte-derived leptin and the brain melanocortin system.Clinical science (London, England : 1979) · 2026Review
- The melanocortin receptors as targets for general obesity: contextualizing clinical failures and analyzing future perspectives.Frontiers in endocrinology · 2026Review
- Pharmacokinetics and safety of TCMCB07, a melanocortin-4 antagonist peptide in dogs.Pharmacology research & perspectives · 2021Article
- Role of the Melanocortin System in the Central Regulation of Cardiovascular Functions.Frontiers in physiology · 2021Review
- Current Mechanistic and Pharmacodynamic Understanding of Melanocortin-4 Receptor Activation.Molecules (Basel, Switzerland) · 2019Review
- Role of melanocortin 4 receptor in hypertension induced by chronic intermittent hypoxia.Acta physiologica (Oxford, England) · 2019Article
- Control of appetite, blood glucose, and blood pressure during melanocortin-4 receptor activation in normoglycemic and diabetic NPY-deficient mice.American journal of physiology. Regulatory, integrative and comparative physiology · 2018Article
- Astragaloside IV Prevents Obesity-Associated Hypertension by Improving Pro-Inflammatory Reaction and Leptin Resistance.Molecules and cells · 2018Article
- Role of the brain melanocortins in blood pressure regulation.Biochimica et biophysica acta. Molecular basis of disease · 2017Review
- Regulation of Blood Pressure, Appetite, and Glucose by CNS Melanocortin System in Hyperandrogenemic Female SHR.American journal of hypertension · 2016Article
- Hypertension in obesity: the role of hypothalamic inflammation.Nature reviews. Endocrinology · 2014Article
- Approach to assessing determinants of glucose homeostasis in the conscious mouse.Mammalian genome : official journal of the International Mammalian Genome Society · 2014Review
- The brain melanocortin system, sympathetic control, and obesity hypertension.Physiology (Bethesda, Md.) · 2014Review
- Neural melanocortin receptors in obesity and related metabolic disorders.Biochimica et biophysica acta · 2014Review
- Genetic dissection of the functions of the melanocortin-3 receptor, a seven-transmembrane G-protein-coupled receptor, suggests roles for central and peripheral receptors in energy homeostasis.The Journal of biological chemistry · 2011Article
- The brain splits obesity and hypertension.Nature medicine · 2011Article
- Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Melanocortins (MSH's) are three structurally related peptides derived from proopiomelanocortin. They regulate several physiologic functions including energy metabolism, appetite, and inflammation. Recent work in rodents has also identified important effects of MSH's, particularly γ-MSH, on sodium metabolism and blood pressure regulation. Normal rats and mice respond to a high sodium diet with an increase in the plasma concentration of γ-MSH, and remain normotensive, while those with genetic or pharmacologic γ-MSH deficiency become hypertensive on a high sodium diet. This hypertension is corrected by exogenous administration of the peptide. Mice lacking the γ-MSH receptor (the melanocortin 3 receptor, Mc3r) also become hypertensive on a high sodium diet but remain so when administered γ-MSH, and infusions of physiologic levels of the peptide stimulate urinary sodium excretion in normal rats and mice, but not in mice with deletion of Mc3r. The salt-sensitive hypertension in rodents with impaired γ-MSH signaling appears due to stimulation of noradrenergic activity, since plasma noradrenaline is increased and the hypertension is rapidly corrected with infusion of the α-adrenoceptor antagonist phentolamine. In contrast to the antihypertensive property of physiologic levels of γ-MSH, intravenous or intracerebroventricular injections of high levels of the peptide raise blood pressure. This occurs in mice lacking Mc3r, indicating an interaction with some other central receptor. Finally, the salt-sensitive hypertension in rodents with disruption of γ-MSH signaling is accompanied by insulin resistance, an observation which offers a new window into the study of the association of salt-sensitive hypertension with insulin resistance and type II diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.